# DoW Peer Reviewed Cancer, Clinical Trial Award

Source: https://welltoldgrants.com/grants/ht942526prcrpcta-dow-peer-reviewed-cancer-clinical-trial-award/  
Official notice: https://www.grants.gov/search-results-detail/362268

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 10 awards worth $45.0 million in total. Applications closed on October 5, 2026.

| Field | Value |
|---|---|
| Opportunity number | HT942526PRCRPCTA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | October 5, 2026 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 10 |
| Total funding | $45.0 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III. • If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial. • Applications are required to include patient advocates. • Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

## Questions people ask

### Is HT942526PRCRPCTA still open?

No. It closed on October 5, 2026. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoW Peer Reviewed Cancer, Clinical Trial Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoW Peer Reviewed Cancer, Clinical Trial Award?

Closed October 5, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $45.0 million in total across about 10 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.